FDA In 'Very Early Stages' of Looking at Centralized Document Review

The FDA is in the beginning stages of looking at a centralized review model for import entry, said a FDA spokeswoman. "FDA is currently exploring the idea of using a 'centralized' review model for import entry review," she said. "This exploration is in the very early stages and will be looking at whether the model is feasible, whether any efficiencies could be expected from such a model, if there would be any benefits to FDA and/or the regulated industry from such a model." An FDA official recently discussed the issue at the National Customs Brokers and Forwarders Association of America conference. (See ITT's Online Archives 12091423 for summary of the FDA official's remarks.)